<DOC>
	<DOCNO>NCT00433927</DOCNO>
	<brief_summary>The FIRE-3 trial multicenter randomize phase III trial investigate 5-FU , folinic acid irinotecan ( FOLFIRI ) plus cetuximab versus FOLFIRI plus bevacizumab first line treatment metastatic colorectal cancer . Planned accrual 284 evaluable patient per treatment arm . The primary study endpoint objective response rate . Secondary endpoint median progression free survival , median overall survival , safety , secondary resection rate .</brief_summary>
	<brief_title>5-FU , Folinic Acid Irinotecan ( FOLFIRI ) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab First Line Treatment Colorectal Cancer ( CRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>KRASWildtype status Histologically confirm adenocarcinoma colon rectum . Stage IV disease . ECOG 02 . Patients consider suitable application chemotherapy . Age 18 75 year . In outpatient treatment . Estimated life expectancy &gt; 3 month . Measurable index lesion accord RECIST criterion . Evaluation tumor manifestation ≤ 2 week prior treatment start . Effective contraception . Adequate hematologic function : leukocyte &gt; = 3000/µl , neutrophil &gt; = 1500/µl , platelet &gt; = 100.000/µ , hemoglobin &gt; = 9g/dl . Bilirubin &lt; = 1,5x upper limit normal ( ULN ) . ALAT ASAT &lt; = 2,5x ULN , case liver metastasis &lt; = 5x ULN . Serum creatinine &lt; = 1,5x ULN . No operation within 4 week prior treatment start . No cytologic biopsy within 1 week prior treatment start . Operation sequel need completely heal . Major operation must expect time study begin , except potential secondary resection liver metastasis . In case secondary resection liver metastasis , bevacizumab must discontinue 68 week prior surgery . No relevant toxicity due prior medical treatment time study entry . KRASMutation tumor Prior treatment direct epidermal growth factor receptor ( EGFR ) . Prior treatment bevacizumab . Prior chemotherapy colorectal cancer , except adjuvant chemotherapy date back &gt; 6 month prior study entry . Experimental medical treatment within 30 day prior study entry . Known hypersensitivity reaction study medication . Pregnant breast feed woman ( pregnancy need excluded test betaHCG ) . Known suspected cerebral metastasis . Clinically significant coronary heart disease , myocardial infarction within last 12 month high risk uncontrolled arrhythmia . Acute subacute ileus , chronic inflammatory bowel disease chronic diarrhea . Symptomatic peritoneal carcinosis . Severe chronic wound , ulcera bone fracture . Uncontrolled hypertension . Severe proteinuria ( nephrotic syndrome ) . Arterial thromboembolic event hemorrhage within 6 month prior study entry ( except tumor bleed surgically treat tumor resection ) . Bleeding diatheses coagulopathy . Full dose anticoagulation . Known DPDdeficiency ( special screening require ) . Known glucuronidationdeficiency ( special screening require ) . Medical history malignant disease within 5 year prior study entry , except basalioma , insitu cervical carcinoma treat curative intent . Known alcohol drug abuse . Medical psychiatric condition contradicts participation study . Limited legal capacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>metastatic</keyword>
</DOC>